Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

Nivolumab is a novel therapeutic option in NSCLC, associated with a significant survival gain compared with Docetaxel. However, predictive biomarkers are lacking. The presence of systemic inflammation has been correlated with poor outcome in many cancer types. We aimed to evaluate whether there is a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Cell Physiol
Hlavní autoři: Russo, Alessandro, Franchina, Tindara, Ricciardi, Giuseppina R.R., Battaglia, Alessandra, Scimone, Antonino, Berenato, Rosa, Giordano, Antonio, Adamo, Vincenzo
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Rapid Communications
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6767577/
https://ncbi.nlm.nih.gov/pubmed/29672849
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcp.26609
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky